What’s Going On With Nordstrom Stock Today?

Nordstrom Inc (NASDAQ: JWN) shares are moving Wednesday after the company reported third-quarter financial results. Here's a rundown of the report.

Nordstrom Inc (NASDAQ:JWN) shares are moving Wednesday after the company reported third-quarter financial results. Here’s a rundown of the report.

What Happened: Nordstrom reported third-quarter revenue of $3.32 billion, which was down from $3.55 billion on a year-over-year basis. The company reported quarterly earnings of 25 cents per share, which was improved from earnings of 20 cents per share in the prior year’s quarter. 

Net sales for Nordstrom Rack decreased 1.8%. Active grew by double-digits and beauty and accessories were up low single-digits compared to 2022.

“In the third quarter we continued to make progress against our priorities, and we’re especially pleased with the resulting improvements in gross margin and earnings,” said Erik Nordstrom, CEO of Nordstrom. 

“Given continued uncertainty and softening consumer spend, we’re remaining agile and focused on serving our customers.”

Nordstrom said it expects full-year 2023 revenue to decline between 4% and 6% versus 2022. The company anticipates full-year adjusted earnings of $1.90 to $2.10 per share.

Following the company’s quarterly results, Telsey Advisory Group analyst Dana Telsey maintained Nordstrom with a Market Perform rating and lowered the price target from $19 to $17.

See Also: What’s Going On With Alibaba Stock Wednesday?

JWN Price Action: Nordstrom shares were down 0.54% at $14.82 at the time of publication, according to Benzinga Pro.

Photo: Mike Mozart from Flickr.

Total
0
Shares
Related Posts
Read More

EXCLUSIVE: How Mojo Plans To Build ‘A Next Level Fan Experience’ In 3 New States

When sportsbook Mojo first launched last September with $100 million in venture capital backing, it proclaimed itself as an athlete "stock market." In other words, users frequent the app to gamble on a player's performance, whether it be in one game, an entire season, or the trajectory of their career.

HOOD

Read More

Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil

Canada's MediPharm Labs has received a GMP certification from the Brazilian governing body, ANVISA. The approval allows for the production of active pharmaceutical ingredients (APIs) and end products for the Brazilian medical cannabis market. MediPharm has already received GMP certifications from the US FDA, the European Union, and Australia's TGA, and holds a drug establishment license from Health Canada. The Brazilian medical cannabis market is projected to reach CAD380m (USD282m) by 2025, according to industry forecasts. MediPharm Labs, which already produces two medical cannabis products with full ANVISA authorization for the Brazilian market, is potentially set for further product authorizations through the regulatory body, according to reports.

MEDIF